Biocon wins U.S. launch date for Prolia and Xgeva biosimilars—Can Amgen keep investors calm?

Amgen (NASDAQ: AMGN) has reached a confidential settlement with Biocon Biologics, a development that could dramatically reshape the U.S. market for bone health biologics. The deal resolves ongoing patent litigation over denosumab biosimilars and clears the way for Biocon to launch its versions, Bosaya and Aukelso, from October 1, 2025. Both biosimilars have already secured U.S. Food and Drug Administration approval, with provisional interchangeability status, positioning them strongly against Amgen’s long-dominant Prolia and Xgeva therapies.

This agreement not only ends a high-stakes courtroom battle in the U.S. District Court for New Jersey but also marks an inflection point for one of Amgen’s most profitable franchises. The company’s strategy of settling rather than endlessly litigating reflects a pragmatic shift as Prolia and Xgeva patents near expiry. For Biocon, the outcome is nothing short of a breakthrough, ensuring it has certainty of entry into one of the world’s most lucrative biologics markets.

Why is the Prolia and Xgeva biosimilar battle so critical for Amgen and Biocon?

Denosumab, the active ingredient in Prolia and Xgeva, has been one of Amgen’s key profit engines for more than a decade. Prolia is used for osteoporosis, while Xgeva addresses bone metastasis and skeletal complications in oncology. Together, they have consistently delivered multi-billion-dollar revenues. In 2024 alone, Prolia generated nearly $2.9 billion in U.S. sales while Xgeva brought in over $1.5 billion, underscoring just how much is at stake as biosimilars prepare to enter.

The original patents protecting Prolia and Xgeva in the U.S. were scheduled to expire in February 2025, but Amgen relied on an extensive suite of secondary patents covering manufacturing methods and delivery innovations to defend its franchise. The company has pursued a strategy of aggressive litigation under the Biologics Price Competition and Innovation Act, suing a host of biosimilar challengers including Sandoz, Samsung Bioepis, Celltrion, Accord, Intas, Fresenius Kabi, Hikma, Henlius, and Biocon itself.

For Biocon, a settlement was always the more commercially viable outcome. Patent litigation is both expensive and unpredictable, with outcomes often hinging on complex technical arguments. By negotiating certainty, Biocon can now align supply chains, commercial planning, and payer engagement strategies ahead of launch.

Why did Amgen decide to settle instead of pursuing prolonged litigation?

From Amgen’s perspective, time is no longer on its side. Patent exclusivity for biologics has historically offered rich cash flows, but once the initial layers of protection fall, challengers are relentless. Amgen has already faced erosion in other franchises such as Neulasta, where biosimilars cut market share sharply within two years of launch. Settling with Biocon, just as it has with Sandoz, Accord, Intas, and Celltrion, allows Amgen to manage the erosion process by staggering launches and potentially securing licensing revenues in return.

Licensing deals like this one give Amgen a degree of predictability. Instead of risking an adverse court judgment that could open the floodgates prematurely, Amgen can ensure biosimilar launches are phased in around specific dates tied to patent expirations. It also provides immediate cost savings by avoiding protracted trials while creating new revenue streams through confidential financial arrangements.

For Biocon, certainty of entry on October 1, 2025 is a competitive advantage over rivals still mired in litigation. With Bosaya and Aukelso already FDA approved, Biocon can hit the ground running while companies like Samsung Bioepis or Hikma remain entangled in ongoing disputes.

What does this mean for the wider biosimilars landscape in 2025?

The settlement comes at a time when the global biosimilars market is accelerating. In Europe, denosumab biosimilars have already entered after patents expired in 2022, leading to sharper pricing competition. In the United States, the denosumab market has been held back by litigation, but 2025 is expected to be the year of transition. Sandoz’s products Jubbonti and Wyost are already lined up for a May 2025 entry, followed by Biocon’s Bosaya and Aukelso in October. Accord, Intas, and Celltrion have also negotiated settlements permitting staggered launches, creating a crowded field of entrants.

As competition intensifies, pricing pressure is inevitable. Historically, biosimilars have driven down biologic treatment costs by 20 to 40 percent within the first few years of market entry. For payers and insurers, denosumab biosimilars offer a long-awaited opportunity to cut costs in treating osteoporosis and cancer-related bone conditions. For patients, greater affordability and broader access could transform care outcomes.

Yet challenges remain. Uptake will depend on physician adoption, patient confidence, and payer contracting. Interchangeability designations, which allow pharmacists to substitute biosimilars without direct physician approval, will play a critical role in shaping adoption curves. Biocon’s ability to secure strong payer support and competitive pricing will determine whether it can carve meaningful market share from Amgen’s entrenched products.

How does this settlement impact Amgen’s stock and investor sentiment?

Amgen’s shares have long been supported by its legacy franchises, but investors are well aware of the looming cliff for Prolia and Xgeva revenues. The settlement with Biocon is likely to be read as a pragmatic move that cushions the blow by ensuring licensing revenues and phasing biosimilar entry. While revenue erosion is inevitable, managed entry could prevent the steep, uncontrolled declines that have hurt other biologics.

For Amgen (NASDAQ: AMGN), the outlook leans neutral to slightly cautious. Institutional investors will be watching how much licensing income offsets declining sales, as well as how successfully the company pivots toward newer therapies in oncology and cardiology. The stock could face pressure if Prolia and Xgeva erosion is sharper than expected, but well-timed licensing and staggered launches may stabilize investor sentiment.

For Biocon Limited (NSE: BIOCON), the settlement represents a significant upside catalyst. Analysts are likely to adopt a more bullish outlook, considering the potential of U.S. biosimilar revenues. Institutional flows, particularly from global funds looking for exposure to Indian pharma innovation, could increase. The entry of Bosaya and Aukelso into the U.S. market is expected to add a strong growth lever to Biocon’s biosimilars portfolio, which already includes launches in insulin and trastuzumab.

Based on current dynamics, investor sentiment on Biocon trends toward a “buy,” while Amgen could remain a “hold” as investors weigh erosion against diversification.

What comes next for denosumab biosimilars and market competition?

Looking ahead, the real battle shifts from the courtroom to the marketplace. Several biosimilar developers remain in litigation, including Samsung Bioepis, which faces an Amgen suit asserting over 30 patents. Hikma and Henlius are also defending against recent BPCIA lawsuits. The outcomes of these disputes will determine how crowded the field becomes by late 2025 and 2026.

For Amgen, the strategy now rests on leveraging its established relationships with physicians, its patient support programs, and its ability to innovate in adjacent therapeutic areas. For Biocon, the key will be execution: launching on time, scaling manufacturing without hiccups, securing payer contracts, and winning physician trust. The provisional interchangeability designation could become a decisive differentiator if leveraged effectively.

Sector-wide, denosumab biosimilars represent a broader inflection point in U.S. biosimilar adoption. The market is watching closely to see whether uptake here mirrors the rapid acceptance seen in Europe or follows a slower, more cautious path like some U.S. oncology biosimilars. If uptake is fast, it could embolden more developers to aggressively target biologics with expiring patents, reshaping the economics of Big Pharma over the next decade.

The settlement between Amgen and Biocon is more than just a legal resolution. It marks the beginning of a commercial battle that will test the strength of biosimilars in the United States. For patients, it offers the promise of more affordable treatment. For Biocon, it unlocks a lucrative growth avenue. For Amgen, it forces a transition from fortress-like patent protection to competitive coexistence. The next 12 months will reveal whether this turning point becomes a textbook case of how biosimilars can finally reset the balance of power in the biologics industry.